Get the daily email about stock.

Please Enter Your Email Address:

By opting in you agree to our Privacy Policy. You also agree to receive emails from us and our affiliates. Remember that you can opt-out any time, we hate spam too!

Bull Trader USA

10 of the Best Stocks to Buy for 2022

Buy Pfizer Stock Because Its Covid Pill Will Be a Big Seller, UBS Says

Shares of Pfizer were upgraded to Buy from Neutral at UBS, with the firm writing that it expects antiviral pill Paxlovid to reach sales of at least $14 billion next year, or 40% above Wall Street expectations. UBS analyst Colin Bristow, in a research note Monday, also boosted the price target on the stock to $60 from $52. Pfizer (ticker: PFE) shares rose 2.5% to $54.10. Bristow wrote how Pfizer’s Covid franchise — Paxlovid and Cominarty, the company’s Covid-19 vaccine — has peak sales potential in 2022 of $50 billion.

Post a Comment